Skip to main content

Table 1 Baseline characteristics of the control and HHcy groups

From: Hyperhomocysteinemia is associated with decreased apolipoprotein AI levels in normal healthy people

Parameters

Control group (n = 1412)

HHcy group (n = 356)

Age, y

41.11 ± 11.44

41.25 ± 12.25

Gender, Males/Females

790/622

196/160

BMI, kg/m2

24.33 ± 3.44

24.68 ± 3.13

SBP, mmHg

120.34 ± 11.26

121.35 ± 11.19

DBP, mmHg

73.04 ± 8.65

73.72 ± 8.89

TC, mmol/L

4.89 ± 0.90

4.87 ± 0.85

LDL-C, mmol/L

2.83 ± 0.73

2.90 ± 0.71

HDL-C, mmol/L

1.29 ± 0.32

1.18 ± 0.25**

TG, mmol/L

1.12 (0.76–1.71)

1.28 (0.88–1.97)**

apoAI, g/L

1.47 ± 0.25

1.38 ± 0.19**

apoB, g/L

0.87 ± 0.20

0.90 ± 0.20

FBG, mmol/L

5.34 ± 0.36

5.38 ± 0.35

FINS, μIU/mL

11.25 (7.40–16.16)

11.41 (8.39–16.40)

HOMA-IR

2.68 (1.74–3.87)

2.72 (1.97–4.01)

Homocysteine, μmol/L

11.04 ± 1.81

26.53 ± 13.68**

  1. Data are means ± SD unless indicated otherwise. TG, FINS and HOMA-IR are shown as median and range. HHcy: hyperhomocysteinemia; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; FBG: fasting blood glucose; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: High-density lipoprotein cholesterol; TG: triglyceride; apoAI: apolipoprotein AI; apoB: apolipoprotein B; FINS: fasting insulin; HOMA-IR: homeostasis model assessment of insulin resistance. * significantly different at P < 0.05 vs control; ** significantly different at P < 0.01 vs control